Sign up to save your podcasts
Or
Share Considerations for offering GLP-1 RAs | With Prof. Carel Le Roux
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Considerations for offering GLP-1 RAs | With Prof. Carel Le Roux
The GLP-1 receptor agonist class offers multifactorial benefits, including reductions in blood glucose, weight loss and cardiovascular protection. But do these vary across the class, and which patients should be offered one? And given they also carry a high risk of gastrointestinal side effects, how should we approach initiating therapy? Join us for a conversation with Prof. Carel Le Roux, Professor of Experimental Pathology and Co-Director of the Metabolic Medicine Group at University College Dublin, and Reader in Investigative Science at Imperial College London.
For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.
Disclosures:
Professor Carel Le Roux has been an advisory board member for Boehringer Ingelheim, Herbalife, GI Dynamics, Johnson & Johnson, and Novo Nordisk.
References:
Funding statement:
This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.
View all episodes
By Liberum IME
5
11 ratings
The GLP-1 receptor agonist class offers multifactorial benefits, including reductions in blood glucose, weight loss and cardiovascular protection. But do these vary across the class, and which patients should be offered one? And given they also carry a high risk of gastrointestinal side effects, how should we approach initiating therapy? Join us for a conversation with Prof. Carel Le Roux, Professor of Experimental Pathology and Co-Director of the Metabolic Medicine Group at University College Dublin, and Reader in Investigative Science at Imperial College London.
For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn.
Disclosures:
Professor Carel Le Roux has been an advisory board member for Boehringer Ingelheim, Herbalife, GI Dynamics, Johnson & Johnson, and Novo Nordisk.
References:
Funding statement:
This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp and Dohme Corp. and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.